A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

NCT05169489 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

BIOLOGICAL: bbT369

Sponsor

Regeneron Pharmaceuticals